Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

pembrolizumab 2radium Ra 223 dichloride 1enzalutamide 1efineptakin alfa 1abiraterone 1Radium-223 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Injections 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Radium-223 × Clear all
NCT03896984 2021-12-29

PHENIX

Bayer

Completed
346 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡